4
Participants
Start Date
June 5, 2017
Primary Completion Date
September 1, 2021
Study Completion Date
October 1, 2021
Lenalidomide or Pomalidomide
Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
REOLYSIN
Patients will receive Reolysin alongside either lenalidomide or pomalidomide
St James's University Hospital, Leeds
Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield
Collaborators (2)
Myeloma UK
OTHER
Oncolytics Biotech
INDUSTRY
Celgene Corporation
INDUSTRY
University of Leeds
OTHER